Skin repair is a multi-phase process involving hemostasis, inflammation, proliferation, and remodeling — each phase presenting distinct molecular targets for peptide research. The proliferation and remodeling phases are particularly relevant to peptide research because they involve the cellular signaling cascades (growth factor receptors, cytokine networks, extracellular matrix synthesis) that peptides are well-positioned to modulate.

The skin is also uniquely accessible for topical administration research, making it a practically important target for peptide delivery system development. Published research on skin peptides spans both systemic administration in wound models and topical delivery in reconstructed skin models, providing rich data on route-activity relationships.

Collagen is the central structural protein of the dermis — approximately 75% of dry skin weight — and its synthesis, organization, and cross-linking determine skin mechanical properties and appearance. Peptides that upregulate collagen synthesis, regulate matrix metalloproteinases (MMPs) that degrade collagen, or improve collagen fiber organization are of primary interest in skin aging and wound healing research.

GHK-Cu is the best-characterized peptide in dermatological research, with a publication history spanning over 40 years since Loren Pickart's initial characterization of its wound healing activity in the 1970s.

For skin research, GHK-Cu's most important documented activities include:

Collagen synthesis upregulation: Published fibroblast culture studies consistently show GHK-Cu increases collagen I and III synthesis. A 2000 study in *Journal of Biomaterials Science* demonstrated GHK-Cu increased collagen production in human fibroblasts by 70% above untreated controls.

MMP regulation: GHK-Cu shows a regulatory (rather than purely inhibitory) effect on MMPs — it upregulates MMP-2 and MMP-9 (which remodel scar tissue to reduce excessive fibrosis) while reducing inflammatory MMP-1 activity. This balanced MMP regulation is associated with improved scar quality in wound models.

Wound contraction acceleration: Multiple animal wound models have shown GHK-Cu accelerates wound contraction, re-epithelialization, and neovascularization compared to vehicle controls. The angiogenic component is well-documented.

Gene expression remodeling: The bioinformatics analysis published by Pickart & Margolina (2018) showed GHK-Cu reverses approximately 70% of aging-associated gene expression changes in skin fibroblasts, providing a molecular basis for its described anti-aging skin effects.

KPV (Lys-Pro-Val) is the C-terminal tripeptide of alpha-MSH (alpha-Melanocyte Stimulating Hormone) and carries the anti-inflammatory activity of the parent molecule without the pigmentation effects mediated by MC1R. In skin biology, this selectivity is particularly valuable — alpha-MSH has potent anti-inflammatory effects in keratinocytes and dermal immune cells, but full alpha-MSH use in skin research risks unintended pigmentation changes in animal models.

KPV research in skin contexts includes:

Keratinocyte anti-inflammatory activity: Published studies show KPV reduces NF-κB activation in keratinocytes exposed to inflammatory cytokines (TNF-α, IL-1β, IFN-γ), reducing production of downstream inflammatory mediators (IL-8, CXCL10, MCP-1) relevant to inflammatory skin conditions like psoriasis and atopic dermatitis models.

Wound healing: KPV has been shown to accelerate wound healing in animal models through its anti-inflammatory effects — by reducing the inflammatory phase duration, it allows earlier transition to the proliferative phase. A 2006 study in *Experimental Dermatology* demonstrated accelerated wound closure with KPV treatment in a mouse excisional wound model.

Oral and topical delivery research: KPV nanoparticle oral delivery has been studied for inflammatory bowel disease (where it reaches gut epithelium), and topical KPV formulations have been studied for skin inflammation. This multi-route research profile makes it relevant to both dermatological and gastrointestinal inflammatory research contexts.

BPC-157 is best known for its musculoskeletal and gastric repair research, but published work on skin wound healing is substantial. Its angiogenic mechanism — upregulation of VEGF and eNOS signaling, leading to neovascularization at wound sites — is directly relevant to skin repair biology.

Published BPC-157 skin wound research includes:

Excisional wound models: Multiple rat studies have shown systemic BPC-157 administration (IP or SC in animals) accelerates wound closure, improves wound breaking strength, and promotes better collagen fiber organization compared to vehicle controls. The angiogenic response is visible histologically as increased vascular density at the wound margin.

Burns: BPC-157 has been studied in burn wound models, where its anti-inflammatory and angiogenic activity has been shown to reduce wound depth progression and accelerate re-epithelialization in partial-thickness models.

Fibroblast activation: In vitro research shows BPC-157 promotes fibroblast migration and proliferation — the cellular basis of wound bed filling — through FAK (focal adhesion kinase) signaling. This mechanism complements its angiogenic activity to provide both vascular and cellular components of wound repair.

The three compounds address different aspects of skin biology, and their selection should be based on the research question:

For collagen and skin remodeling research: GHK-Cu has the most established evidence base and the most detailed mechanistic literature. It is the compound of choice for research into collagen synthesis, scar quality, and aging-related skin changes.

For inflammatory skin condition models: KPV's melanocortin receptor selectivity and NF-κB suppression make it the most appropriate compound for psoriasis, atopic dermatitis, and contact dermatitis model research where inflammation is the primary endpoint.

For acute wound healing research: BPC-157's angiogenic mechanism is particularly relevant to wound healing models where neovascularization is a key endpoint. For full-thickness excisional wound models, BPC-157 has a strong published evidence base.

Combination approaches: GHK-Cu + BPC-157 combinations address complementary aspects of wound repair (collagen synthesis + angiogenesis) and have been studied together in some published wound models. KPV can be added to any combination for anti-inflammatory coverage during the acute inflammatory phase.

All three peptides are research-use-only materials. They are not approved cosmetic or therapeutic agents and are studied in laboratory and preclinical contexts.